drugset
drugset / Trial / NCT05254171

Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

NCT05254171 ↗

Phase 2/3 Recruiting 600 enrolled Panbela Therapeutics, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study is a randomized, double-blind, placebo-controlled, multicenter study of standard treatment with nab-paclitaxel and gemcitabine with or without SBP-101 in subjects previously untreated for metastatic pancreatic ductal adenocarcinoma (PDA), including subjects who have received prior neoadjuvant or adjuvant treatment.

Timeline

Start
2022-08-08
Primary completion
2026-08-29
Completion
2027-01-01

Drugs

EvaluationDrugModalityDoseRoute
Subject IVOSPEMIN Other / unclassified — Subcutaneous
Background Gemcitabine Small molecule — —
Background Paclitaxel Small molecule — —

Indications

pancreatic ductal adenocarcinoma